We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Hana Biosciences, a biopharmaceutical company focused on advancing cancer care, today announced that the company has submitted a New Drug Application (NDA) for Zensana (ondansetron HCl) Oral Spray to the U.S. Food and Drug Administration seeking marketing approval for the prevention of nausea and vomiting associated with chemotherapy, radiotherapy, and post-operative induced nausea and vomiting.
The FDA and a federal district court have removed all obstacles for Israeli company Teva and Indian company Ranbaxy to begin marketing their generic versions of Merck's $4.4 billion cholesterol drug Zocor, the drugmakers said June 23, the day Merck's patent expired.
The FDA has granted accelerated approval of Bristol-Myers Squibb's cancer drug Sprycel for the treatment of a rare type of leukemia, the agency has announced.
Biogen Idec and Elan's recalled multiple sclerosis (MS) drug Tysabri has been approved by European regulators for patients with the severest cases of the disease.
Genaera Corporation announced today that it has received signed securities purchase agreements from institutional investors, including existing shareholders, for the purchase of approximately 35.6 million shares of its common stock and warrants to purchase approximately 26.7 million shares of its common stock at a purchase price of $0.70385 per unit for aggregate gross proceeds of approximately $25.0 million.
Radius announced today that it has acquired exclusive worldwide rights, excluding Japan, to a new class of selective estrogen receptor modulators (SERMs) discovered by Eisai Co., Ltd.
VaxGen, Inc. announced today that it has realized gross proceeds of approximately $79.0 million through the sale of a portion of its common shares in Celltrion, Inc. VaxGen also granted the purchasers an exclusive option to acquire the remainder of its Celltrion shares by December 31, 2006.
The Athlone-based pharmaceutical company, Élan, has announced that its multiple sclerosis treatment drug Tysabri will be on the market in Ireland from next month.